Protecting patients from adverse drug events: Propoxyphene, PIMs, and drugs to avoid in older adults

Journal of Managed Care Pharmacy

Volumn 17, Issue 1, 2011, Pages 60-69

  Curtiss, Frederic R ^a   Fairman, Kathleen A ^a  

^a Academy of Managed Care Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; HYDROCODONE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE;

ARTHRITIS; CARDIOVASCULAR RISK; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FALLING; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MANAGED CARE; MEDICARE; MORTALITY; PATIENT SAFETY; PATIENT SELECTION; PRESCRIPTION; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; SIGNAL NOISE RATIO;

EID: 78650888660     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.1.60     Document Type: Editorial

References (49)

1. U.S. Food and Drug Administration. Bisphosphonates (osteoporosis drugs): label change-atypical fractures update including Fosamax, Fosamax Plus D, Actonel, Actonel with calcium, Boniva, Atelvia, and Reclast. October 13, 2010. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm229244.htm. Accessed December 28, 2010.
2. Kolata G. When drugs cause problems they are supposed to prevent. NY Times. October 16, 2010. Available at: http://www.nytimes.com/2010/10/17/health/policy/17drug.html?_r=2. Accessed December 28, 2010.
3. U.S. Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. Makes regulatory decisions on RECORD and TIDE trials. September 23, 2010. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/UCM226975.htm. Accessed December 28, 2010.
4. Rosen CJ. Revisiting the rosiglitazone story-lessons learned. N Engl J Med. 2010;363(9):803-06. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMp1008233. Accessed December 28, 2010.
5. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med. 2010;363(16):1489-91. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMp1010788. Accessed December 28, 2010.
6. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes. 2010;3(5):538-45. Epub 2010 Aug 24.
7. Takeda Pharmaceuticals. Prescribing information. Actos (pioglitazone hydrochloride) tablets. September 2009. Available at: http://www.actos.com/actospro/prescribinginfo.aspx. Accessed December 28, 2010.
8. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968-76.
9. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979-86.
10. Becker WC, O'Connor PG. The safety of opioid analgesics in the elderly: new data raise new concerns. Arch Intern Med. 2010;170(22):1986-88.
11. U.S. Food and Drug Administration. Opioid drugs and risk evaluation and mitigation strategies (REMS). September 23, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm. Accessed December 28, 2010.
12. U.S. Department of Health and Human Services. National action plan to assure the appropriate use of therapeutic agents in the elderly. Fed Regist. April 15, 2002; 67(72):18206-07. Available at: http://www.gpo.gov/fdsys/pkg/FR-2002-04-15/pdf/02-9048.pdf. Accessed December 28, 2010.
13. Graf J. Analgesic use in the elderly: the "pain"and simple truth. Arch Intern Med. 2010;170(22):1976-78.
14. U.S. Food and Drug Administration. Xenodyne agrees to withdraw propoxyphene from the U.S. market. November 19, 2010; updated December 1, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234350.htm. Accessed December 28, 2010.
15. Wilson D. Darvon pulled from the market by F.D.A. NY Times. November 19, 2010. Available at: http://prescriptions.blogs.nytimes.com/2010/11/19/darvon-pulled-from-market-by-f-d-a/?ref=health. Accessed December 29, 2010.
16. U.S. Food and Drug Administration. Darvocet N 50 and Darvocet N 100 (propoxyphene napsylate and acetaminophen tablets, USP). September 25, 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017122s061s062lbl.pdf. Accessed December 29, 2010.
17. Dooren JC. Drug maker agrees to withdraw pain pills from market. Wall Street J. November 21-22, 2010:B4. Available at: http://online.wsj.com/article/SB10001424052748704170404575624580619320348.html. Accessed December 29, 2010.
18. National Committee for Quality Assurance. NCQA releases HEDIS 2006; new measures address overuse, follow-up. July 7, 2005; updated July 19, 2005. Available at: http://www.ncqa.org/tabid/277/Default.aspx/. Accessed December 29, 2010.
19. Pugh MJ, Hanlon JT, Zeber JE, Bierman A, Cornell J, Berlowitz DR. Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using HEDIS 2006 quality measure. J Manag Care Pharm. 2006;12(7):537-45. Available at: http://www.amcp.org/data/jmcp/research_537_545.pdf.
20. Gurwitz JH, Rochon P. Improving the quality of medication use in elderly patients: A not-so-simple prescription. Arch Intern Med. 2002;162(15):1670-72.
21. National Committee for Quality Assurance. HEDIS Table DAE-A: High-risk medications. HEDIS 2009, vol 2. Available at: http://www.ncqa.org/Portals/0/HEDISQM/HEDIS2009/NDC/Word%20Tables%20for%20HEDIS%202009/Table%20DAE-A.doc. Accessed December 29, 2010.
22. National Committee for Quality Assurance. HEDIS 2010 final NDC lists. Use of high-risk medications in the elderly. Table DAE-A. Available at: http://www.ncqa.org/tabid/1091/Default.aspx. Accessed December 29, 2010.
23. National Committee for Quality Assurance. The state of health care quality 2009. Available at: http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC_2009.pdf. Accessed December 29, 2010.
24. Zhang Y, Baicker K, Newhouse JP. Geographic variation in the quality of prescribing. N Engl J Med. 2010;363(21):1985-88. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMp1010220. Accessed December 29, 2010.
25. Fick DM, Waller JL, Maclean JR, et al. Potentially inappropriate medication use in a Medicare managed care population: associated with higher costs and utilization. J Manag Care Pharm. 2001;7(5):407-13. Available at: http://www.amcp.org/data/jmcp/Research-407-413.pdf.
26. Pugh MJ, Fincke BG, Bierman AS, et al. Potentially inappropriate prescribing in elderly veterans: are we using the wrong drug, wrong dose, or wrong duration? J Am Geriatr Soc. 2005;53(8):1282-89.
27. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA. 2001;286(22):2823-29. Available at: http://jama.ama-assn.org/cgi/reprint/286/22/2823. Accessed December 29, 2010.
28. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997;157(14):1531-36.
29. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. consensus panel of experts. Arch Intern Med. 2003;163(22):2716-24. Available at: http://archinte.ama-assn.org/cgi/reprint/163/22/2716. Accessed December 29, 2010.
30. Centers for Medicare & Medicaid Services. 2009 0HEDIS, HOS and CAHPS measures for reporting by Medicare managed care contractors. December 9, 2008. Available at: https://www.cms.gov/SpecialNeedsPlans/Downloads/HEDIS09Measures_120908.pdf. Accessed December 29, 2010.
31. Barnett MJ, Perry PJ, Langstaff JD, Kaboli PJ. Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector Medicare HMOs. J Manag Care Pharm. 2006;12(5):362-70. Available at: http://amcp.org/data/jmcp/research_362-370.pdf.
32. Florida Medication Safety Initiative, Florida Quality Improvement Organization. Medication safety: propoxyphene (Darvon, Darvocet). Available at: http://www.qide.org/shared/content/de_documents/Patient%20Safety/propoxyphene_V1.pdf. Accessed December 29, 2010.
33. May S, Mort JR, Sailor R. Potentially inappropriate medications (PIMs) on the Prairie: propoxyphene use in North Dakota and South Dakota. Dakota Nurse Connection. South Dakota Board of Nursing. Available at: http://www.ndhcri.org/HealthCareProfessionals/PatientSafety/DrugSafety/pimsontheprairie. pdf. Accessed December 29, 2010.
34. Morris C, Cantrill J. Preventable drug-related morbidity indicators in the U.S. and U.K. J Manag Care Pharm. 2002;8(5):372-77. Available at: http://www.amcp.org/data/jmcp/Contemporary%20Subjects-372-377.pdf.
35. Curtiss FR. Medical errors, adverse medical events and PDRM. J Manag Care Pharm. 2002;8(5):400. Available at: http://www.amcp.org/data/jmcp/Editorial_400-405.pdf.
36. Steinman MA, Rosenthal GE, Landefeld CS, Bertenthal D, Kaboli PJ. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. Arch Intern Med. 2009;169(14):1326-32. Available at: http://archinte.ama-assn.org/cgi/reprint/169/14/1326. Accessed December 30, 2010.
37. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755-65.
38. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63(2):136-47. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000562/pdf/bcp0063-0136.pdf. Accessed December 30, 2010.
39. Courtman BJ, Stallings SB. Characterisation of drug-related problems in elderly patients on admission to a medical ward. Can J Hosp Pharm. 1995;48(3):161-66.
40. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31(4):199-205.
41. Cunningham G, Dodd TR, Grant DJ, McMurdo ME, Richards RM. Drugrelated problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age Ageing. 1997;26(5):375-82.
42. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556-64. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMsa020703. Accessed December 30, 2010.
43. Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol. 1992;47(4):M111-M115.
44. Kaufman MB, Brodin KA, Sarafian A. Effect of prescriber education on the use of medications contraindicated in older adults in a managed Medicare population. J Manag Care Pharm. 2005;11(3):211-19. Available at: http://www.amcp.org/data/jmcp/Research_211-219.pdf.
45. Briesacher B, Limcangco R, Simoni-Wastila L, Doshi J, Gurwitz J. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment. J Am Geriatr Soc. 2005;53(6):991-96.
46. Curtiss FR. Evidence-based medicine: Which drugs are truly contraindicated for use in older adults? J Manag Care Pharm. 2005;11(3):259-61. Available at: http://www.amcp.org/data/jmcp/Editorials_259-61.pdf.
47. National Committee for Quality Assurance. HEDIS 2009 Physician measures. Available at: http://www.ncqa.org/Portals/0/HEDISQM/HEDIS2009/HEDIS_2009_Physician_Measures.pdf. Accessed December 30, 2010.
48. Crownover BK, Unwin BK. Implementation of the Beers criteria: sticks and stones-or throw me a bone. J Manag Care Pharm. 2005;11(5):416-17. Available at: http://www.amcp.org/data/jmcp/editorial_416-417.pdf.
49. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(9):1825-32.